Security Investigators Link Joshua Meacham to Fraudulent Reports Submitted To Colorado Marijuana Enforcement Division & Colorado Department of Public Health & Environment

DENVER, March 30, 2016 – Mary’s Medicinals, developer of award-winning cannabis products including the first Transdermal Cannabis Patch, today announced that due to an ongoing pattern of harassment, fraudulent reporting and the dissemination of false information, it has filed a lawsuit in United States District Court for the District of Colorado against Joshua Meacham, founding partner of RXGreen Cannabis, for charges including libel, slander, civil conspiracy, intentional interference with prospective business relations, and intentional interference with contractual relations.

“The overwhelming majority of people in the cannabis industry are incredibly honest and hardworking,” said Nicole Smith, founder & CEO, Mary’s Medicinals. “Unfortunately, when the leader of a business trusted by the state and the community demonstrates a pattern of under-handed, deceitful behavior, action must be taken. After uncovering the depth of harassment and slander, we were left with no other recourse but to take legal action to halt this attack on us and our community.”

After learning of several bizarre reports from dispensaries, Mary’s staff began investigating and gathering evidence about questionable emails, phone calls and social media posts from individuals allegedly masquerading as customers claiming that they or their family members suffered extreme health problems from Mary’s products.

“To me, the most despicable part of all of this is that someone would pose as a patient who truly needed help just to try to harm our business,” said Smith. “These actions undermine the heart and soul of our industry and everything we are working so hard to accomplish to further patient rights and their access to clean, consistent cannabis therapeutics. This pettiness harms all of us.”

Further investigation suggested that Meacham had submitted fraudulent reports about Mary’s products under multiple false identities to the Marijuana Enforcement Division and the Colorado Department of Public Health & Environment. After submitting CORA public records requests to confirm the IP addresses of the submitted reports, Mary’s investigators traced the reports from various aliases to an IP address registered to Meacham’s home in Snowmass, Colo. and an email tied to a business registered under his name in Arizona.

The investigation was continued and validated by Security Grade Protective Services, Ltd and subsequently joined by the Colorado Marijuana Enforcement Division, which is considering additional action. As required by law, all of the fraudulent claims were thoroughly investigated by the Colorado Marijuana Enforcement Division and Colorado Department of Public Health & Environment, at significant expense both to Colorado taxpayers and Mary’s Medicinals.

“It is frustrating that as a company that has invested so much into our industry-leading accountability and ensuring our products are safe, consistent and accurate, we had to repeatedly waste resources participating in these time-consuming investigations,” said Smith.

RXGreen continues to use content on its website that appears to be “borrowed” from an old website. Archived Version of original Mary’s site from 2014.

“While imitation surely is the sincerest form of flattery, we do hold published patent applications for our products, and we don’t encourage competitors to ‘borrow’ our innovations or content from our website,” said Smith. “Sadly, the evidence seems to suggest that RXGreen’s entire business strategy revolved around imitation, scare tactics and trying to trash competitors at the expense of patients and the entire medical cannabis movement.”


About Mary’s Medicinals:

Mary’s Medicinals is a wellness company innovating at the intersection of engineering and horticulture. Mary’s is focused on transforming how people view and utilize cannabis, developing trusted products that isolate the benefits of cannabis and other vital plant extracts for optimum patient care. More information is available at:

The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficiency of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. If you are taking any medication or are under treatment for any disease, please consult your health care professional about potential interactions or other possible complications before using these products. The Federal Food, Drug and Cosmetic Act requires this notice.

Please follow and share: